Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 8 · newest first

  1. Amplified EPOR / JAK2 Genes Define a Unique Subtype of Acute Erythroid LeukemiaBlood Cancer Discovery · 2022
  2. PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant TransformationBlood Cancer Discovery · 2022
  3. Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome ProgressionBlood Cancer Discovery · 2022
  4. Transcriptional Plasticity Drives Leukemia Immune EscapeBlood Cancer Discovery · 2022
  5. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II ExpressionBlood Cancer Discovery · 2022
  6. Perspectives on the Risk-Stratified Treatment of Multiple MyelomaBlood Cancer Discovery · 2022
  7. The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2 -Mutant PreleukemiaBlood Cancer Discovery · 2022
  8. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaBlood Cancer Discovery · 2022
  9. Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid LeukemiaBlood Cancer Discovery · 2022
  10. Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21Blood Cancer Discovery · 2022
  11. Efficient Algorithms Unlock Understanding of Clonal Evolution in CancerBlood Cancer Discovery · 2022
  12. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19Blood Cancer Discovery · 2022
  13. Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid LeukemiaBlood Cancer Discovery · 2022
  14. ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute LeukemiaBlood Cancer Discovery · 2022
  15. Reconstructing Complex Cancer Evolutionary Histories from Multiple Bulk DNA Samples Using PairtreeBlood Cancer Discovery · 2022
  16. In This IssueBlood Cancer Discovery · 2022
  17. Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid LeukemiaBlood Cancer Discovery · 2022
  18. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell LymphomaBlood Cancer Discovery · 2022
  19. CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished ImmunityBlood Cancer Discovery · 2022
  20. BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesBlood Cancer Discovery · 2021
  21. Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell TherapyBlood Cancer Discovery · 2021
  22. Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesBlood Cancer Discovery · 2021
  23. Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2021
  24. Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic TargetBlood Cancer Discovery · 2021
  25. Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsBlood Cancer Discovery · 2021
  26. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-ReactivityBlood Cancer Discovery · 2021
  27. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic MalignanciesBlood Cancer Discovery · 2021
  28. Overcoming Acquired Epigenetic Resistance to BTK InhibitorsBlood Cancer Discovery · 2021
  29. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesBlood Cancer Discovery · 2021
  30. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell TherapyBlood Cancer Discovery · 2021
  31. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaBlood Cancer Discovery · 2021
  32. Checkpoint Blockade + Chemotherapy: the Right Combination for AML?Blood Cancer Discovery · 2021
  33. Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic IndicatorsBlood Cancer Discovery · 2021
  34. Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaBlood Cancer Discovery · 2021
  35. Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid LeukemiaBlood Cancer Discovery · 2021
  36. Bispecific Antibodies in Multiple Myeloma: Present and FutureBlood Cancer Discovery · 2021
  37. Scalable Manufacturing of CAR T Cells for Cancer ImmunotherapyBlood Cancer Discovery · 2021
  38. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional AnalysisBlood Cancer Discovery · 2021
  39. ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA SplicingBlood Cancer Discovery · 2021
  40. Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1Blood Cancer Discovery · 2021
  41. A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase InhibitorsBlood Cancer Discovery · 2021
  42. Mutation Signatures of Pediatric Acute Myeloid Leukemia and Normal Blood Progenitors Associated with Differential Patient OutcomesBlood Cancer Discovery · 2021
  43. Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid LeukemiaBlood Cancer Discovery · 2021
  44. Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple MyelomaBlood Cancer Discovery · 2021
  45. Bortezomib Induces Immunogenic Cell Death in Multiple MyelomaBlood Cancer Discovery · 2021
  46. Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic LeukemiaBlood Cancer Discovery · 2021
  47. Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic TherapyBlood Cancer Discovery · 2021
  48. Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaBlood Cancer Discovery · 2021
  49. Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway ActivationBlood Cancer Discovery · 2021
  50. An Evolutionary Approach to Clonally Complex Hematologic DisordersBlood Cancer Discovery · 2021